Nurix Q3: $549.8M Profit on Roche Upfront, $1.1B Cash, Bexobrutideg Enters Phase 3
NRIX has more than doubled off its 52-week low of $9 on elevated volume (2.2× avg).
Summary
Nurix posted a $549.8M Q3 profit driven by the Roche collaboration upfront, with $1.1B in cash funding operations into 2029. Bexobrutideg entered Phase 3 while NX-2127 was discontinued.
Key Events · Earnings and Guidance · NRIX
-
Roche Upfront Drives $549.8M Q3 Profit
Net income of $549.8M ($4.73 diluted EPS) on $673.1M revenue, including $653.2M in license revenue from the $700M Roche upfront payment recognized in the quarter.
-
Cash Position Reaches $1.1B
Cash, cash equivalents and marketable securities totaled $1.1B as of August 31, 2026, up from $592.9M at fiscal year-end 2025, funding operations into the second half of 2029.
-
Bexobrutideg Enters Phase 3
First patient dosed in DAYBreak CLL-306, a registrational Phase 3 trial comparing bexobrutideg to pirtobrutinib in ~620 patients with relapsed/refractory CLL/SLL.
-
NX-2127 Discontinued
Nurix discontinued further clinical development of zelebrudomide (NX-2127) as part of strategic prioritization of its wholly owned oncology portfolio.
Analysis · NRIX · Life Sciences
A $549.8M quarterly profit—a sharp reversal from the $86.4M loss a year ago—was driven entirely by the $653.2M license revenue recognized from the $700M Roche upfront payment. The balance sheet now shows $1.1B in cash and marketable securities, up from $592.9M at fiscal year-end, which funds operations into the second half of 2029. The full Roche agreement filed as an exhibit reveals the complete economics: a 40/60 development cost split, 50/50 US profit share, and up to $1.6B in additional milestone payments plus tiered royalties. Bexobrutideg advanced into a registrational Phase 3 trial (DAYBreak CLL-306) with the first patient dosed in August 2026, while the company discontinued zelebrudomide (NX-2127) to focus resources. The Gilead collaboration was also extended by two years for a $10M fee.
How filings like this one have moved
In the 30 days to Oct 13, 2026, 36.5% of the 993 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NRIX was trading at $22.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $9.00 to $28.23. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.